Mississauga, Canada

Daniel Pereira


Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 2011-2012

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Daniel Pereira in Cancer Treatment

Introduction

Daniel Pereira is an accomplished inventor based in Mississauga, Canada. He has made significant contributions to the field of medical research, particularly in the development of treatments for cancer. With a total of two patents to his name, Pereira's work focuses on innovative methods to inhibit specific receptors involved in disease progression.

Latest Patents

Pereira's latest patents include groundbreaking inventions related to the Inhibition of macrophage-stimulating protein receptor (RON). The first patent provides antibodies or fragments thereof, including human antibodies, that are specific for the Macrophage-Stimulating Protein Receptor (MSP-R or RON). These antibodies inhibit RON activation, offering potential therapeutic avenues for treating diseases such as cancer. The second patent similarly focuses on antibodies that bind specifically to human RON protein, reinforcing the importance of this receptor in cancer treatment.

Career Highlights

Daniel Pereira is currently associated with Imclone LLC, where he continues to advance his research and development efforts. His work has garnered attention in the scientific community, highlighting the potential of his inventions to impact cancer therapies significantly.

Collaborations

Pereira collaborates with Jennifer O'Toole, leveraging their combined expertise to enhance the effectiveness of their research initiatives.

Conclusion

Daniel Pereira's innovative work in the field of cancer treatment exemplifies the critical role of inventors in advancing medical science. His patents on RON inhibitors represent a promising step forward in the fight against cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…